Organisation paid for research Program year 2021 Source: CMS Open Payments

Arocha Research Center

Neither a doctor nor a teaching hospital

Research payments

$73,134

6 payments

Through program year 2021, Arocha Research Center is reported as receiving $73,134 in research payments, across 6 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$9,416	2
2020	Research	$12,519	2
2019	Research	$51,200	2

Breakdown

Who paid Research payments · program years 2019–2021

Otsuka Pharmaceutical Development & Commercialization, Inc. $73,134 6 payments

Studies the money was for Research payments · program years 2019–2021

A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole Opc34712 in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $46,424 1 payment
A 12-Week, Multicenter, Active-Treatment Extension Trial to Evaulate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type $11,795 2 payments
A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $8,816 1 payment
A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $5,500 1 payment
A 12-Week, Multicenter, Active-Treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type $600 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.